Cybin Inc (CYBN) Stock Price, Quote & News

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology

Sector: Healthcare

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

LiquidThetaOptions Nov. 8 at 11:04 PM

💎 LiquidTheta® Live Actionable Trade Asset: $CYBN Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.88- $2.30 Scale out: $7.31-$12.52 Profit Potential : 447% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Iightning Nov. 8 at 2:10 PM

1ightning® Options Trade Alert (Actionable) | Buy $CYBN Nov 21 $8 Call | Enter: $0.54 Exit: $1.02 | Profit: 88.89% ROI | https://1ightning.com

0 · Reply

fromthesedgegrass Nov. 8 at 12:38 AM

$CYBN Friends, I've been watching this stock for just a few weeks/months. And I see that most analysts say it will be a 10-bagger within a year. My question: how long have they been saying that - for 5 years? And how seriously do you take that prediction?

0 · Reply

LiquidThetaOptions Nov. 7 at 9:27 PM

💎 LiquidTheta® Live Actionable Trade Asset: $CYBN Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.34- $1.64 Scale out: $5.21-$8.93 Profit Potential : 191% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

HughJasol Nov. 7 at 7:18 PM

$CYBN this won’t see 7 again… will bounce around between 4 and 6 for the next 9 months …. And when it is at 4 and goes to 6 these clown bulls will say “it’s up 50%”… absolute garbage.

1 · Reply

thepalace2007 Nov. 7 at 4:02 PM

$CYBN buy at this now price easy money maker here very soon

0 · Reply

kriscory69 Nov. 7 at 2:50 PM

$CYBN green day in the end

0 · Reply

kriscory69 Nov. 6 at 7:28 PM

$CYBN reversal hopefully

1 · Reply

Fox4321 Nov. 6 at 4:40 PM

$CYBN Market capitalization in October 2025: about 150 millions Market capitalization in November 2025: about 300 milions Stock price: the same… Dilution machine Cybin’management must start to create value for the owners of the company: THE SHAREHOLDERS. NOW!

1 · Reply

starbucks_cups_with_rum Nov. 6 at 3:38 PM

$CYBN is holding up better than tech right now

1 · Reply

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 7:30 AM EST - 3 days ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 5 days ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 8 days ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 11 days ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 18 days ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 6 weeks ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 11, 2025, 3:59 PM EDT - 2 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 7:30 AM EDT - 2 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 4, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 2 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 2 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 2 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 13, 2025, 5:30 PM EDT - 3 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 7, 2025, 7:30 AM EDT - 3 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 17, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 4 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 10:03 PM EDT - 4 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 4 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 5 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 12, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 11, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 3, 2025, 7:30 AM EDT - 5 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

May 22, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 20, 2025, 7:30 AM EDT - 6 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025, 7:30 AM EDT - 6 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 14, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 8, 2025, 7:30 AM EDT - 6 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 1, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Apr 23, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 21, 2025, 8:00 AM EDT - 7 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Feb 10, 2025, 9:48 PM EST - 9 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 10 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 10 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 10 months ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 11 months ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Oct 18, 2024, 2:30 PM EDT - 1 year ago

Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +

DAVA EQNR

Oct 15, 2024, 12:30 PM EDT - 1 year ago

Cybin: Top Value Psychedelic Stock

LiquidThetaOptions Nov. 8 at 11:04 PM

0 · Reply

Iightning Nov. 8 at 2:10 PM

1ightning® Options Trade Alert (Actionable) | Buy $CYBN Nov 21 $8 Call | Enter: $0.54 Exit: $1.02 | Profit: 88.89% ROI | https://1ightning.com

0 · Reply

fromthesedgegrass Nov. 8 at 12:38 AM

0 · Reply

LiquidThetaOptions Nov. 7 at 9:27 PM

0 · Reply

HughJasol Nov. 7 at 7:18 PM

$CYBN this won’t see 7 again… will bounce around between 4 and 6 for the next 9 months …. And when it is at 4 and goes to 6 these clown bulls will say “it’s up 50%”… absolute garbage.

1 · Reply

thepalace2007 Nov. 7 at 4:02 PM

$CYBN buy at this now price easy money maker here very soon

0 · Reply

kriscory69 Nov. 7 at 2:50 PM

$CYBN green day in the end

0 · Reply

kriscory69 Nov. 6 at 7:28 PM

$CYBN reversal hopefully

1 · Reply

Fox4321 Nov. 6 at 4:40 PM

1 · Reply

starbucks_cups_with_rum Nov. 6 at 3:38 PM

$CYBN is holding up better than tech right now

1 · Reply

Iightning Nov. 6 at 2:46 PM

1ightning® Options Trade Alert (Actionable) | Buy $CYBN Nov 21 $8 Call | Enter: $0.54 Exit: $1.02 | Profit: 88.89% ROI | https://1ightning.com

0 · Reply

Mcahill Nov. 6 at 2:34 PM

$ATAI $MNMD $CMPS $CYBN Another bloodbath

0 · Reply

Kopelius Nov. 6 at 12:35 PM

$CYBN https://finance.yahoo.com/news/cybin-announce-second-quarter-financial-123000941.html

0 · Reply

thepalace2007 Nov. 6 at 3:53 AM

$CYBN great time to buy

0 · Reply

Mcahill Nov. 5 at 8:55 PM

$ATAI $MNMD $CMPS $CYBN Wow they really fucked us good

3 · Reply

stoxx0007 Nov. 5 at 8:46 PM

$CMPS $CYBN $MNMD $GHRS $PSIL

1 · Reply

grumpygoose Nov. 5 at 8:27 PM

$CYBN got bitch slapped off the 200 day

0 · Reply

NeedsAwin Nov. 5 at 7:30 PM

$CYBN hahahaha this is the only stock in the sector trading at the same pric it was last week.

1 · Reply

outlawinvestor1 Nov. 5 at 7:06 PM

$CYBN https://vimeo.com/1131030497?fl=pl&fe=ti

0 · Reply

starbucks_cups_with_rum Nov. 5 at 6:47 PM

$CYBN took an L

0 · Reply

kriscory69 Nov. 5 at 6:14 PM

$CYBN added again

0 · Reply

kriscory69 Nov. 5 at 5:43 PM

$CYBN thonk bottom is in we'll see

0 · Reply

Market Cap	150.62M
Revenue (ttm)	0.00
Net Income (ttm)	-81.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	488,500
Avg Vol	884,654
Day's Range	N/A - N/A
Shares Out	25.19M
Stochastic %K	7%
Beta	0.66
Analysts	Strong Sell
Price Target	$80.60